Yaoyao Sun1, Kristyn Huffman, William R Freeman, Lingyun Cheng. 1. From the Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, USA. Y. Sun is now at the Department of Ophthalmology, Ophthalmology & Optometry Center, Peking University People's Hospital, Beijing, China.
Abstract
PURPOSE: To develop a mesoporous silica drug delivery system and target drop-free care after cataract surgery with a single subconjunctival injection. SETTING: Laboratory. DESIGN: Experimental animal study. METHODS: Ketorolac was infiltration-loaded into sol-gel mesoporous silica particles encapsulated with poly(allylamine hydrochloride) and poly(sodium 4-styrenesulfonate) using a layer-by-layer adsorption technique (SG-Ket-LBL). The formulation was subjected to an in vitro and in vivo drug release study in addition to ocular toxicology evaluation. RESULTS: Thermogravimetric analysis revealed that the drug loading efficiency was 4.4% for the SG-Ket-LBL particles. The in vivo safety study demonstrated that the formulation was well tolerated after subconjunctival injection and aqueous humor pharmacokinetics showed sustained therapeutic drug release for the targeted time window of 6 to 8 weeks. CONCLUSIONS: Findings indicated that sol-gel mesoporous silica could be used as a drug carrier for subconjunctival administration. The tested formulation, SG-Ket-LBL, provided therapeutic ketorolac for 6 to 8 weeks, which might be used for a single subconjunctival injection to replace nonsteroidal anti-inflammatory drug eyedrops after cataract surgery.
PURPOSE: To develop a mesoporous silica drug delivery system and target drop-free care after cataract surgery with a single subconjunctival injection. SETTING: Laboratory. DESIGN: Experimental animal study. METHODS: Ketorolac was infiltration-loaded into sol-gel mesoporous silica particles encapsulated with poly(allylamine hydrochloride) and poly(sodium 4-styrenesulfonate) using a layer-by-layer adsorption technique (SG-Ket-LBL). The formulation was subjected to an in vitro and in vivo drug release study in addition to ocular toxicology evaluation. RESULTS: Thermogravimetric analysis revealed that the drug loading efficiency was 4.4% for the SG-Ket-LBL particles. The in vivo safety study demonstrated that the formulation was well tolerated after subconjunctival injection and aqueous humor pharmacokinetics showed sustained therapeutic drug release for the targeted time window of 6 to 8 weeks. CONCLUSIONS: Findings indicated that sol-gel mesoporous silica could be used as a drug carrier for subconjunctival administration. The tested formulation, SG-Ket-LBL, provided therapeutic ketorolac for 6 to 8 weeks, which might be used for a single subconjunctival injection to replace nonsteroidal anti-inflammatory drug eyedrops after cataract surgery.
Authors: Thomas S Dietlein; Jens F Jordan; Christoph Lüke; Andrea Schild; Sven Dinslage; Guenter K Krieglstein Journal: Acta Ophthalmol Date: 2008-05-20 Impact factor: 3.761
Authors: Joseph P Gira; Reginald Sampson; Steven M Silverstein; Thomas R Walters; Jamie Lynne Metzinger; Jonathan H Talamo Journal: Patient Prefer Adherence Date: 2017-03-08 Impact factor: 2.711